ShennonBio Raises $12M and Names Cyril Konto CEO

Li Sun is changing jobs at the company she founded just as its science is changing jobs too. Shennon Biotechnologies has raised $12M, appointed Cyril Konto, MD, as CEO, and moved Li Sun, PhD, from CEO to Founder, President, and CTO as the San Francisco biotech turns a broad discovery platform into three named oncology programs.

The financing came from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, and Saras Capital, with continued support from DCVC, Foundation Capital, and AV8 Ventures. ShennonBio reports $25M raised to date, and the company says the new capital will support its integrated technology platform and advance T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma toward the clinic.

The leadership change gives the announcement its operating meaning. ShennonBio is no longer asking only whether its technology can find rare immune-cell interactions at unusual scale; it is organizing the company around whether those discoveries can become development candidates, partnerships, regulatory filings, and eventually clinical evidence.

What ShennonBio Announced

In its September 14 financing announcement, ShennonBio did not identify a lead investor, valuation, security type, or named round. The clean description is a $12M financing, not a Series A or another inferred label. The amount follows a $13M seed round announced in 2023, which reconciles with the company's reported $25M total funding.

Li Sun remains at the center of the scientific work. The founder will lead scientific strategy, technology development, and pipeline innovation as President and CTO. Cyril Konto takes the CEO role with more than 20 years of oncology development, company-building, and transaction experience, including his most recent role as President and CEO of Ichnos Glenmark Innovation.

That experience sits close to ShennonBio's current technical problem. In July 2025, AbbVie licensed IGI's trispecific T-cell engager ISB 2001 for $700M upfront and up to $1.225B in potential milestone payments, plus royalties. The transaction does not predict ShennonBio's outcome, but it gives Cyril Konto direct experience at the point where a multispecific oncology asset meets large-company development and partnership economics.

How the Platform Supports Three Oncology Programs

ShennonBio's integrated engine tries to keep several expensive discovery steps connected. PINTRA uses proprietary human tumor datasets and computational methods to identify surface and intracellular targets. TCELERATOR performs ultra-high-throughput functional screening, which the company says can evaluate more than 10M single-cell interactions at once and millions of therapeutic candidates. AFFINIS predicts, designs, and optimizes antibody binders and T-cell receptors, while SERIS is designed to identify potential off-target cross-reactivity earlier through AI-enabled safety assessment.

The company has translated those capabilities into three initial pipeline programs. SBT-121 is a dual-targeting trispecific antibody T-cell engager for small cell lung cancer. SBT-201 is an antibody T-cell engager for ovarian cancer. SBT-425 is a TCR-based T-cell engager for hepatocellular carcinoma.

The split between antibody-based and TCR-based engagers matters because it broadens the kinds of cancer biology ShennonBio hopes to address. Antibody T-cell engagers generally work against targets on a tumor cell's surface. TCR-based engagers can potentially recognize intracellular proteins after fragments are presented through HLA, opening a larger but technically demanding target universe.

Why the Leadership Handoff Matters

Founders often become inseparable from the technology they created, especially in biotech, where scientific judgment can shape a company for years before a product reaches patients. ShennonBio's leadership structure acknowledges that invention and development-stage execution require overlapping but different kinds of attention. Li Sun can keep driving the science while Cyril Konto owns the broader company-building work around the pipeline.

The timing is deliberate in practical terms, even if the company did not disclose the internal process behind it. ShennonBio has four named platform components, three oncology programs, reported datasets spanning more than 10,000 tumor samples and more than 11M single cells, relationships involving more than 15 institutions, and approximately 6,000 square feet of laboratory and office space near UCSF Mission Bay. Each asset creates options, but each also creates a demand for prioritization.

Capital cannot advance every option equally. Development teams must decide which program gets resources first, what evidence supports an IND package, which capabilities belong inside the company, and where a partnership can add speed or expertise without giving away the logic that makes the platform valuable. The CEO appointment makes those choices part of the financing story rather than a separate personnel note.

What the $12M Is Expected to Fund

Over the next two years, ShennonBio plans to move a development candidate toward an IND filing and Phase 1 clinical development. The company also expects to pursue licensing opportunities for selected therapeutic programs and explore partnerships around binder prediction and generation, clinical-toxicity prediction, and its proprietary datasets. Those are company plans, not completed milestones, and the public pipeline remains in discovery or preclinical development.

The financing therefore sits between two different kinds of proof. ShennonBio has reported technical scale across screening, data, and program creation. The next phase asks whether that scale can produce a candidate with the pharmacology, safety, manufacturability, regulatory package, and partner confidence required to move into people.

Biotechnology markets have become less patient with platform stories that never narrow into products. ShennonBio is responding by naming programs, assigning leadership for the development phase, and attaching a two-year operating horizon to the capital. That combination gives investors, partners, and potential hires a more concrete set of milestones than a general promise to discover better targets.

What This Signals for Precision Immunotherapy

Solid-tumor immunotherapy remains difficult because tumor biology, antigen selection, immune-cell function, and safety risk are entangled. A target can be biologically interesting and still fail because the binder is weak, the healthy-tissue risk is unacceptable, or the therapeutic format cannot produce a useful response. ShennonBio's thesis is that joining human tumor data, functional screening, computational design, and early safety prediction can reduce those handoff failures.

The company has not yet shown clinical validation for that thesis, and its sample, cell, and institutional-network figures are company-reported. Still, the financing makes the next test legible. ShennonBio must choose where its platform deserves to become a product, then carry that choice through the slower disciplines that medicine imposes.

Li Sun built the company around finding rare immune interactions that conventional workflows could miss. Cyril Konto now joins as ShennonBio begins deciding which of those discoveries can earn a development program, a regulatory file, and a place in the clinic. The company has divided the work before the pipeline forces the division for it.